ArticleExpert review of proteomics2013
Promotion of cancer metastasis: candidate validation using an iTRAQ-based approach.
Article in Expert review of proteomics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- Analysis of CacyBP/SIP, ERK1/2, and p38 Expression in Low- and High-Grade Papillary Urothelial Carcinoma.Cancer medicine · 2026Article
- Downregulation of CacyBP by CRISPR/dCas9-KRAB Prevents Bladder Cancer Progression.Frontiers in molecular biosciences · 2021Article
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Evaluation of: Ghosh D, Li Z, Tan XF, Lim TK, Mao Y, Lin Q. RAQ based quantitative proteomics approach validated the role of calcyclin binding protein (CacyBP) in promoting colorectal cancer metastasis. Mol. Cell Proteomics 12(7), 1865-1880 (2013). The use of iTRAQ-based relative quantification is demonstrated by Ghosh et al. to analyze the downstream effectors of a calcyclin-binding protein, which is proposed to promote colorectal cancer progression. These findings are reviewed and discussed in relation to the need to establish robust in vitro model cell lines for identification of cancer-specific pathways and to confirm the leads generated by proteomic analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.